Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Inquiry Memorial
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation Report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
Support and FAQs
NHS Psychological Support
Support Groups
Infected Blood Support Schemes
Hepatitis C Testing
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
Lynne Kelly told the Inquiry that following the Lindsay Tribunal, Westminster and the Welsh Government kept repeating the mantra: "there was no fault, the circumstances were different".
Published on:
16 August, 2024
The Welsh Government voted in favour of a public inquiry.
Published on:
16 August, 2024
Simon Hamilton, chair of Haemophilia Northern Ireland, told the Inquiry that the position in Northern Ireland was largely to follow the Department of Health in England.
Published on:
16 August, 2024
Robert James told the Inquiry: "the way haemophilia doctors saw us ... we were their 'children'. Because it was predominantly a young person's disease at the time because older haemophiliacs had died of bleeding before we had cryo, there was an awful lot of young children, and for haemophilia doctors, they saw us like that. And so they would just not refer us on to an appropriate immunologist".
Published on:
20 September, 2024
Robert James told the Inquiry that Drs Mark Winter and Has Dasani were good at keeping up to date with medical knowledge in the field.
Published on:
20 September, 2024
Letters were sent out to parents with their children's AIDS test results. There is also some evidence of two group meetings for parents being held at the RMCH.
Published on:
30 September, 2024
Profilate HT gained market share as a consequence of growing confidence that its technique of "wet heat treatment" reduced, although did not eliminate, the risk of infection with non-A non-B Hepatitis as well as inactivating HIV.
Published on:
27 August, 2024
Profilate licensed with the following warning: "This product is prepared from units of human plasma which have been tested and found nonreactive for Hepatitis Associated Antigen. However, it is recognized that presently available methods are not sensitive enough to detect all units of potential infectious plasma and the risk of transmitting hepatitis is still present".
Published on:
27 August, 2024
Over the years the text of the Profilate warning was amended to take account of changes to screening tests, but the final sentence remained unchanged.
Published on:
27 August, 2024
Profilate HT was provided on a named patient basis in the UK
Published on:
27 August, 2024
The licensing authority required references to heat treatment to be that it was intended to "reduce the risk of transmission of infectious agents" rather than making claims about it reducing the risks of HIV or non-A non-B Hepatitis by name.
Published on:
27 August, 2024
When marketing Factor 8 Concentrates produced from plasma of US origin and the European based material one, no distinction was made between the labelling nor the accompanying information sheets in order for clinicians to pick whichever they wanted to use.
Published on:
23 July, 2024
The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma).
Published on:
27 August, 2024
Companies could voluntarily submit product data sheets to a compendium produced annually by the Association of British Pharmaceutical Industry ("ABPI").
Published on:
27 August, 2024
Data sheets and product leaflets relating to Kryobulin did not mention AIDS, HTLV-3, LAV or HIV.
Published on:
27 August, 2024
Hyland targeted gay men for whole blood donations for the purpose of obtaining hyperimmunised plasma, and while Hyland did not use plasma recovered following this process for its own factor concentrates it did sell this on to Alpha, and Alpha then used that plasma as part of its pools when manufacturing factor concentrates.
Published on:
27 August, 2024
Dr Entwistle stated that the Cambridge RTC had arrangements for a night porter who would telephone the on-call doctor, if services were required out of hours, who could authorise for blood to be issued to hospital blood banks.
Published on:
25 July, 2024
Dr Entwistle in his evidence stated that the Oxford RTC unlike other RTCs sent its plasma to the Plasma Fractionation Laboratory (PFL) in Oxford, instead of the Blood Products Laboratory (BPL), and PFL sent the fractionated products directly to the Oxford Haemophilia Centre.
Published on:
25 July, 2024
Dr Entwistle said the fact he remained unaware at the time that there were shortages of blood donors in nearby areas underlined the need for rationalisation of the service.
Published on:
25 July, 2024
Dr Entwistle told the Inquiry that the Oxford RTC could have collected more donations in order to assist centres with shortages.
Published on:
25 July, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2364
Page
2365
Page
2366
Page
2367
Current page
2368
Page
2369
Page
2370
Page
2371
Page
2372
…
Next page
Next
Last page
Last